2076975 2077203
최종편집 2024-03-28 16:29 (목)
November KOSDAQ pharmaceuticals components devastated, ST PharmㆍSeegene aced
상태바
November KOSDAQ pharmaceuticals components devastated, ST PharmㆍSeegene aced
  • Hyeokgi Lee, Newsmp
  • 승인 2021.12.06 19:24
  • 댓글 0
이 기사를 공유합니다

74 out of 107 stocks saw double-digit drops… KRW 3.5063 trillion in market cap evaporated

ST PharmㆍSeegene jumped more than 40%... HumasisㆍiNtRON Biotechnology also   rose double-digits

In November, the KOSDAQ pharmaceuticals components also suffered a slump.

According to the Korea Exchange, 94 out of 107 components of the pharmaceuticals index fell last month, and 74 stocks recorded double-digit declines.

In particular, the stock price of Scm Life plunged 31.8%, while that of Nibec, Peoplebio, NKMAX, Hans Biomed, Eutilex, Jetema, Hugel, Tego Science, and Huons Global also fell more than 20%.

On the other hand, only 13 stocks saw their stock price increase during the same period. Among the 13 stocks, ST Pharm and Seegene soared by more than 40%, and Humasis and iNtRON Biotechnology posted nearly 20% of the increase.

In the KOSPI pharmaceuticals index, despite the decline in most stocks, the index’s market capitalization increased due to the performance of the three major bio companies, but the KOSDAQ pharmaceuticals index’s market capitalization fell KRW 3.563 trillion from KRW 51.1074 trillion to KRW 47.611 trillion, collapsing the KRW 50 trillion mark.

Hugel’s market capitalization fell by KRW 480.7 billion, the largest drop, and Eubiologics and HK Inno.N also shrank by more than KRW 300 billion.

Moreover, NKMAX’s market capitalization decreased by KRW 250 billion, and KolmarBNH, Pharma Research Products, Dongkook Pharmaceutical, BNC Korea, Nature Cell, Huons Global, Medy-Tox, Chabiotech, Sam Chun Dang Pharm, Enzychem Lifesciences, ABL Bio, Korea Pharm, and Jetema also lost more than KRW 100 billion.

Nevertheless, Seegene’s market capitalization increased by KRW 1.1751 trillion within a month to reach the KRW 4 trillion mark, while ST Pharm rose by KRW 707.1 billion, Celltrion pharm by KRW 245.2 billion, iNtRON Biotechnology by KRW 127.2 billion, and Humasis by KRW 109.5 billion.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.